UCB Cimzia Phase III Crohn's data

UCB (Euronext:UCB) said its Cimzia certolizumab ( CDP 870) met the primary endpoints in the Phase III PRECiSE 1 and 2 trials to treat moderate to severe Crohn's disease. The double-blind, placebo-controlled, international trials enrolled a total of 1,330 patients, split about evenly between the trials. PRECiSE 1's two co-primary endpoints were the percentage of patients with clinical response at week six and the percentage of patients with clinical response at weeks six and 26. PRECiSE 2's primary endpoint was the percentage of patients with clinical response at week 26. Clinical response was defined as a decrease of at least 100 points from baseline in Crohn's disease activity index (CDAI) score. ...